Overactive Bladder - Results from #2320

The influence of melatonin and agomelatine on urodynamic parameters in experimental overactive bladder model - preliminary results January 19, 2012

Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity - Abstract January 19, 2012

Behaviour change to treat overactive bladder syndrome - Abstract January 18, 2012

Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates - Abstract January 17, 2012

Effects and mechanisms of phosphodiesterase type 5 inhibitors on rats with overactive bladder January 12, 2012

Overactive bladder: Diagnosis and management - Abstract January 9, 2012

Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: A multicentre, open-label, prospective observational study - Abstract January 6, 2012

Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey - Abstract January 5, 2012

High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms - Abstract January 4, 2012

Neuroprotection of green tea catechins on surgical menopause-induced overactive bladder in a rat model December 26, 2011

Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: Pooled analysis of two open-label extension studies - Abstract December 23, 2011

Current management and future perspectives of overactive bladder (OAB) pharmacotherapy - Abstract December 22, 2011

Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder - Abstract December 21, 2011

Behavioral versus drug treatment for overactive bladder in men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial - Abstract December 20, 2011

Characteristics and impact of interrupted sleep in women with overactive bladder - Abstract December 12, 2011

Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder December 9, 2011

Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist - Abstract December 6, 2011

Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity - Abstract December 5, 2011

Blebbistain, a myosin II inhibitor, as a novel strategy to regulate detrusor contractility in a rat model of partial bladder outlet obstruction - Abstract December 5, 2011

Bladder outlet obstruction induced expression of prostaglandin E(2) receptor subtype EP4 in the rat bladder: A possible counteractive mechanism against detrusor overactivity - Abstract December 5, 2011

Page 117 of 125